Neutrophil-lymphocyte ratio and Platelet to lymphocyte ratio as markers for predicting the severity in COVID-19 patients: A Prospective Observational study.
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- AIIMS Hospital
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- To evaluate the ability of the NLR and PLR to predict severity in COVID-19 patients.
Study Overview
Brief Summary
Of note, a high incidence of lymphopenia in COVID-19 patients has been seen. In addition, the baseline neutrophil-to-lymphocyte ratio (NLR) has been confirmed as a potential prognostic indicator for patients in various other studies. So identifying severe patients in the early stage is of great significance for reducing the clinical morbidity and improving the cure rate. So, we aimed to compare peripheral blood neutrophil to lymphocyte count ratio (NLR) and platelet to lymphocyte ratio to explore the clinical indicator that can predict severity of COVID-19 in the early stage.
Patients clinical symptoms and signs will be obtained from electronic medical records or files when the patient is admitted and receiving the treatment. All the relevant routine laboratory investigations will be noted from the electronic data records at the time of receiving the treatment. If required follow-up on telephone consultation will be done on the discharge.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 6.00 Year(s) to 99.00 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •Only confirmed cases of COVID-19 diagnosed on the basis of ICMR standard.
Exclusion Criteria
- •1.Age below 6 years.
- •2.Pregnant patients 3.Dialysis dependent patients 4.All trauma patients 5.Any malignancy 6.Any psychiatric illness 7.Consent not given.
Outcomes
Primary Outcomes
To evaluate the ability of the NLR and PLR to predict severity in COVID-19 patients.
Time Frame: Baseline-on admission
Secondary Outcomes
- 1. Mortality(2. Length of hospitalization)